Cantor Fitzgerald Reiterates “Overweight” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Monday, Benzinga reports. They presently have a $140.00 price objective on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 30.72% from the stock’s previous close.

Several other brokerages have also recently issued reports on JAZZ. Morgan Stanley dropped their price objective on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Friday, July 12th. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. Finally, Wells Fargo & Company cut their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $107.10 on Monday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The stock has a 50 day moving average price of $109.75 and a 200 day moving average price of $111.97. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $137.57. The firm has a market capitalization of $6.61 billion, a P/E ratio of 22.08, a P/E/G ratio of 1.34 and a beta of 0.57.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Rise Advisors LLC increased its holdings in Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 203 shares during the period. Versant Capital Management Inc grew its position in Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.